ISDA

Deposition Date 2012-01-05

Release Date 2012-09-12

Last Version Date 2023-09-13

Entry Detail

PDB ID:

3VDD

Keywords:

VIRUS

Title:

Structure of HRV2 capsid complexed with antiviral compound BTA798

Biological Source:

Source Organism:

Human rhinovirus 2 (Taxon ID: 12130)

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

3.20 Å

R-Value Free:

0.27

R-Value Work:

0.22

R-Value Observed:

0.23

Space Group:

P 21 2 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Protein VP1
Chain IDs:A
Chain Length:283
Number of Molecules:1
Biological Source:Human rhinovirus 2

UniProt ID:P04936 Pfam ID:PF00073, PF02226

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Protein VP2
Chain IDs:B
Chain Length:261
Number of Molecules:1
Biological Source:Human rhinovirus 2

UniProt ID:P04936 Pfam ID:PF00073, PF02226

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Protein VP3
Chain IDs:C
Chain Length:237
Number of Molecules:1
Biological Source:Human rhinovirus 2

UniProt ID:P04936 Pfam ID:PF00073, PF02226

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Protein VP4
Chain IDs:D
Chain Length:69
Number of Molecules:1
Biological Source:Human rhinovirus 2

UniProt ID:P04936 Pfam ID:PF00073, PF02226

Ligand Molecules

BT8

Primary Citation

An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.

Feil, S.C, Hamilton, S, Krippner, G.Y, Lin, B, Luttick, A, McConnell, D.B, Nearn, R, Parker, M.W, Ryan, J, Stanislawski, P.C, Tucker, S.P, Watson, K.G, Morton, C.J.Show

ACS Med Chem Lett 3 303 307 (2012)

PMID: 24900468 DOI: 10.1021/ml2002955

Abstact

Respiratory infections caused by human rhinovirus are responsible for severe exacerbations of underlying clinical conditions such as asthma in addition to their economic cost in terms of lost working days due to illness. While several antiviral compounds for treating rhinoviral infections have been discovered, none have succeeded, to date, in reaching approval for clinical use. We have developed a potent, orally available rhinovirus inhibitor 6 that has progressed through early clinical trials. The compound shows favorable pharmacokinetic and activity profiles and has a confirmed mechanism of action through crystallographic studies of a rhinovirus-compound complex. The compound has now progressed to phase IIb clinical studies of its effect on natural rhinovirus infection in humans.

Legend

Protein

Chemical

Disease

Primary Citation of related structures